Walvax Biotechnology Co., Ltd. (SHE:300142)
10.24
-0.01 (-0.10%)
May 14, 2025, 2:45 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Autonomous Vaccine | 4.08B |
Log In |
Log In |
Log In |
Log In |
Intermediate Products | 17.22M |
Log In |
Log In |
Log In |
Log In |
Intermediate Products Growth | -36.61% |
Log In |
Log In |
Log In |
Log In |
Technical Services | 11.02M |
Log In |
Log In |
Log In |
Log In |
Technical Services Growth | -33.40% |
Log In |
Log In |
Log In |
Log In |
Other Business | 7.92M |
Log In |
Log In |
Log In |
Log In |
Other Business Growth | 3.51% |
Log In |
Log In |
Log In |
Log In |
Non-immunization Program Vaccines | - |
Log In |
Log In |
Log In |
Log In |
Immunization Program Vaccines | - |
Log In |
Log In |
Log In |
Log In |
13-valent Pneumococcal Polysaccharide Conjugate Vaccine | - |
Log In |
Log In |
Log In |
Log In |
23-valent Pneumococcal Polysaccharide Vaccine | - |
Log In |
Log In |
Log In |
Log In |
Haemophilus Influenza Type B | - |
Log In |
Log In |
Log In |
Log In |
Freeze-dried AC Vaccine Group Meningococcal Polysaccharide Conjugate Vaccine | - |
Log In |
Log In |
Log In |
Log In |
Group A and C Meningococcal Polysaccharide Vaccine | - |
Log In |
Log In |
Log In |
Log In |
ACYW135 Meningococcal Polysaccharide Vaccine | - |
Log In |
Log In |
Log In |
Log In |
Absorbed Acellular Diphtheria Combined Vaccine | - |
Log In |
Log In |
Log In |
Log In |
Other | - |
Log In |
Log In |
Log In |
Log In |
Production | - |
Log In |
Log In |
Log In |
Log In |
Production Growth | - |
Log In |
Log In |
Log In |
Log In |
Research and Development | - |
Log In |
Log In |
Log In |
Log In |
Research and Development Growth | - |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In |
China | 3.83B |
Log In |
Log In |
Log In |
Log In |
China Growth | -20.34% |
Log In |
Log In |
Log In |
Log In |
Overseas | 287.54M |
Log In |
Log In |
Log In |
Log In |
Overseas Growth | 1.46% |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In |
Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In |